BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33416185)

  • 1. miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma.
    Lu N; Zhang M; Lu L; Liu YZ; Zhang HH; Liu XD
    Oncol Rep; 2021 Feb; 45(2):706-716. PubMed ID: 33416185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
    Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
    PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Tan X; Li Z; Ren S; Rezaei K; Pan Q; Goldstein AT; Macri CJ; Cao D; Brem RF; Fu SW
    Breast Cancer Res; 2019 Aug; 21(1):89. PubMed ID: 31391072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of miR‑490‑3p in colorectal cancer predicts poor prognosis and promotes cell proliferation and invasion by targeting RAB14.
    Wang B; Yin M; Cheng C; Jiang H; Jiang K; Shen Z; Ye Y; Wang S
    Int J Oncol; 2018 Sep; 53(3):1247-1256. PubMed ID: 29916545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.
    Qi L; Bart J; Tan LP; Platteel I; Sluis Tv; Huitema S; Harms G; Fu L; Hollema H; Berg Av
    BMC Cancer; 2009 May; 9():163. PubMed ID: 19473551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
    Lee J; Kim HE; Song YS; Cho EY; Lee A
    Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1.
    Song LN; Qiao GL; Yu J; Yang CM; Chen Y; Deng ZF; Song LH; Ma LJ; Yan HL
    J Exp Clin Cancer Res; 2020 Jun; 39(1):114. PubMed ID: 32552766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.
    Yu J; Xie F; Bao X; Chen W; Xu Q
    Mol Cancer; 2014 May; 13():121. PubMed ID: 24885626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
    Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
    J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis.
    Liu X; Yao W; Xiong H; Li Q; Li Y
    Cancer Biomark; 2020; 29(2):277-290. PubMed ID: 32675392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells.
    Wang C; Xie XX; Li WJ; Jiang DQ
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10410-10421. PubMed ID: 31841195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21.
    Wu H; Chen S; Liu C; Li J; Wei X; Jia M; Guo J; Jin J; Meng D; Zhi X
    Eur J Pharmacol; 2021 Oct; 909():174401. PubMed ID: 34358482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR‑425‑5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN.
    Xiao S; Zhu H; Luo J; Wu Z; Xie M
    Oncol Rep; 2019 Dec; 42(6):2550-2560. PubMed ID: 31638259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
    BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
    Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O
    Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.